Industry News
March 11, 2010Pioneering sequencing projects unveil triggers for disease
March 10, 2010Amylin, Lilly gear up for big FDA ruling
March 10, 2010Cytokinetics gets orphan drug status for ALS drug
March 10, 2010Neuropharm mulls voluntary liquidation as it waits for deal
March 10, 2010EKR names interim president, CEO
March 10, 2010Novartis offers $955M deal to snare Transgene drug option
March 10, 2010Biotech VCs, Big Pharma stepping outside the comfort zone
March 9, 2010In 9-3 vote, expert panel backs InterMune's pirfenidone
March 9, 2010Abbott buys Facet Biotech for $450M
March 9, 2010Tocagen raises $7.8M; ISTA gets PDUFA date;
March 9, 2010AutoImmune calls it quits
March 9, 2010Cellzome partners with GSK on inflammatory diseases
March 9, 2010Who's the next biotech buyout target?
March 9, 2010InterMune trading halted on panel review
March 9, 2010'Externalization' takes center stage at Bio-Europe Spring
March 9, 2010Ark in sales talks after regulators demand new trial
March 9, 2010Exelixis chops 270 jobs in restructuring
March 8, 2010ExonHit, bioMerieux nix colon cancer program
March 8, 2010FDA OKs Cell Therapeutics' manufacturing plant
March 8, 2010InterMune stock rise ahead of meeting
March 8, 2010XenoPort cuts 50% of workforce
March 8, 2010The biotech spring arrives in Barcelona
March 8, 2010AZ's Recentin flunks head-to-head trial with Avastin
March 8, 2010Infections and deaths force Biogen, Roche to suspend blockbuster program
March 5, 2010Alnara rises from Altus' ashes
March 5, 2010BMS talks pipeline at analyst meeting
March 5, 2010Chinese drugmaker could partner with Abbott
March 5, 2010InterMune gears up for panel review
March 5, 2010Apixaban superior to Lovenox in study
March 5, 2010Resverlogix looks to succeed where Pfizer failed